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Abstract
Objective: To determine whether thrombocytosis is a 
prognostic factor for epithelial ovarian cancer and its 
relationship with 3-year overall survival in epithelial ovarian 
cancer patients.
Methods: This study is a retrospective cohort study 
using medical record of patients with epithelial ovarian 
cancer registered in cancer registry of Oncology Division 
in Obstetrics and Gynecology Department, Dr. Cipto 
Mangunkusumo National General Hospital from January 
2014 - July 2016. Data were collected when subjects were 
fi rst until diseases outcomes identifi ed in 3 years.
Result: Out of 220 subjects, 132 (60%) were patients 
with advanced stage epithelial ovarian cancer (stage II/
III/IV). 94 (42.7%) subjects had thrombocytosis. Patients 
with advanced stage of disease had higher risk of having 
thrombocytosis than the ones with earlier stage (p=0.005; 
OR=2.329). Correlation between thrombocytosis and 3-year 
overall survival was known to be insignifi cant (p=0.555). 
There was shorter mean time survival between patients with 
thrombocytosis and the ones without but the there was 
no signifi cant difference in hazard ratio between the two 
groups (p  = 0.399).
Conclusions: Thrombocytosis is not a prognostic factor 
in patients with epithelial ovarian cancer. There is also no 
signifi cant difference of 3-year overall survival between 
patients with or without thrombocytosis.
Keywords: epithelial ovarian carcinoma, prognosis, 
thrombocytosis.
Abstrak
Tujuan: Membuktikan bahwa trombositosis sebagai faktor 
prognosis kesintasan pada pasien kanker ovarium jenis 
epitelial dan hubungannya terhadap kesintasan 3 tahun 
pasien kanker ovarium  jenis epitelial.
Metode: Penelitian ini merupakan studi kohort retrospektif 
menggunakan data rekam medis pasien kanker ovarium 
epitelial yang terdaftar pada cancer registry Departemen 
Obstetri dan Ginekologi Divisi Onkologi Rumah Sakit 
Cipto Mangunkusumo pada tahun Januari 2014-Juli 2016. 
Pengamatan dilakukan saat subjek pertama kali didiagnosis 
akhir pengamatan selama 3 tahun.
Hasil: Didapatkan 220 subjek penelitian yang merupakan 
populasi terjangkau dan memenuhi kriteria inklusi dan 
eksklusi. Dari 220 subjek penelitian, 132 (60%) dari 220 
subjek penelitian merupakan pasien dengan kanker 
ovarium stadium lanjut (Stadium II/III/IV). Trombositosis 
didapatkan pada 94 orang subjek penelitian (42,7%). Pasien 
dengan kanker stadium lanjut memiliki risiko trombositosis 
yang lebih tinggi dibandingkan subjek pada stadium awal 
(p=0,005;OR=2,329). Trombositosis secara statistik tidak 
bermakna pada kesintasan 3 tahun (p=0,555). Terdapat 
mean time survival yang lebih rendah pada pasien dengan 
trombositosis tetapi tidak ada perbedaan hazard ratio yang 
bermakna antara subjek dengan atau tanpa trombositosis 
(p=0,399).
Kesimpulan: Trombositosis bukan merupakan faktor 
prognostik pada pasien kanker ovarium jenis epitelial dan 
tidak terdapat hubungan antara trombositosis dan 3 tahun 
pada pasien dengan kanker ovarium jenis epithelial. 
Kata kunci: karsinoma ovarium epithelial,  prognosis, 
trombositosis.
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INTRODUCTION
Ovarian cancer is one of the most common 
cancers suffered by women along with breast, 
cervical, lung and rectal cancers. Epithelial 
ovarian cancer is the most deadly gynecological 
malignancy, representing 21,980 new cases 
in 2014 in the United States and about 14.270 
(64.9%) of which outcome were death.1 Only 30% 
of ovarian cancer patients can be diagnosed at 
an early stage, while the rest are already in an 
advanced stage.2
Cancer is a pathological condition that can be 
associated with thrombocytosis. This particular 
condition could be caused by the release of 
cytokines from several malignancies. Studies 
have shown that thrombocytosis in epithelial 
ovarian cancer is associated with increased 
levels of IL-6 in serum which will ultimately 
stimulate thrombopoiesis, therefore increasing 
thrombocyte production.3 Platelets would 
infl uence natural evolution of cancer through 
several mechanisms, namely protection against 
tumor cells and simultaneously produce several 
Growth Factors (GF) and enzymes such as 
lysophosphatidic acid, Metalloproteinase Matrix 
(MMP), thymidine phosphorylase, and vascular 
endothelial growth factor (VEGF) which play a 
role in angiogenesis, invasion and metastasis of 
tumor cells.4,5
Thrombocytosis is associated with increased 
chance of recurrence for various cancer, including 
ovarian cancer (HR: 2.37; 95%CI: 1.82, 3.09).6 
Previous researched have also studied that there 
is a linear relationship between thrombocytosis, 
stage of cancer, and decreased survival in 
patients with ovarian cancer.7 Growth factors 
and cytokines examination, while proven to be 
effective in determining the prognosis of cancer 
patients, remains to be costly for many countries, 
including Indonesia. Meanwhile, platelet 
examination is a routine blood test performed 
on patients, easy to do and relatively low cost 
compared to examination of growth factors and 
cytokines such as VEGF, PDGF and others.
This study aims to determine the relationship 
between thrombocytosis and 3-year survival of 
patients with epithelial ovarian cancer.
METHODS
An retrospective study was performed 
in National General Hospital Dr. Cipto 
Mangunkusumo on January 2014 to July 2019. 
The study population were all epithelial ovarian 
cancer patients diagnosed between January 2014 
and July 2016 and have completed appropriate 
treatment according to the procedure set. 
Patients with suspected sepsis, having another 
malignancy, or having incomplete medical 
record were excluded in this study. Consecutive 
sampling method was done in this study. Patients 
were then divided into thrombocytosis and non-
thrombocytosis group. Thrombocytosis was 
defi ned as having thrombocyte in serum of more 
than 400.000 unit / dL. Baseline characteristics 
were analyzed and compared. Bivariate 
analysis between subjects’ characteristics and 
thrombocytosis was done. Survival analysis using 
Kaplan-Meier was done to all subjects and overall 
survival between study groups were compared. 
Ethical clearance was issued from health research 
and ethical committee in Faculty of Medicine, 
Universitas Indonesia.
RESULTS
A total of 220 ovarian cancer patients had 
completed treatment in Dr. Cipto Mangunkusumo 
National General Hospital, therefore included 
in this study. Among those 220 subjects, 132 
(60%) of whom were diagnosed with advanced 
ovarian cancer (stage II-IV), 94 (42.7%) of whom 
had thrombocytosis, 215 (97.7%) of whom had 
elevated CA-125 level, and 15 (6,8%) of whom 
died during the follow up period. Baseline 
characteristics of subjects can be found on 
Table 1.
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In order to determine the involvement of 
other variables in determining thrombocytosis 
level in ovarian cancer patients, bivariate analysis 
between groups was done. Result of bivariate 
analysis in this study can be found in Table 2.
In order to compare overall survival rate 
of patients with and without thrombocytosis, 
survival analysis using Kaplan-Meier was done in 
this study. The Kaplan-Meier graph for this study 
can be found on fi gure 1.
In order to compare overall survival between 
groups, cox-regression analysis was done. It was 
found that there were no signifi cant difference of 
survival time between study groups. (p = 0,555). 
The result of cox-regression analysis can be 
found on Table 3.
DISCUSSION
In this study, it was found that patients 
with advanced cancer had a higher risk for 
thrombocytosis (p = 0.005; OR = 2.329). These 
results are similar to previous studies such as 
studies.3 In the mouse model, demonstrated an 
increase in hepatic thrombopoietin in response 
to excess tumor-derived interleukin-6 (IL-6) at 
higher tumor grading or advanced disease stage 
which then forms a positive feedback loop and 
promotes further tumor growth.3
Furthermore, thrombocytosis is known to 
have a relationship to overall survival (OS). In this 
study, researchers found that the presence or 
absence of thrombocytosis was not statistically 
signifi cant in 3-years survival (p = 0.555). Further 
survival analysis showed a lower mean survival 
rate between the groups with thrombocytosis 
of 2.766 years compared to the group without 
thrombocytosis of 2.857 years. However, hazard 
analysis showed that thrombocytosis was not 
statistically signifi cant to 3-years survival (p = 
Figure 1. Kaplan-Meier Graph between Study Groups
Table 1. Baseline Characteristics of Subjects
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0.399). That thrombocytosis was not a signifi cant 
prognostic factor in ovarian cancer patients.8 
The results found in the study showed that 
thrombocytosis had a stronger correlation with 
other patient characteristics such as ascites and 
other hematologic abnormalities, especially 
anemia.8 Suggested that thrombocytosis was not 
a signifi cant prognostic factor in patients with 
advanced stages. However, if the stage is stratifi ed 
by early and advanced stages, thrombocytosis 
can be a signifi cant prognostic factor in early 
stage patients.6
Differences in therapy given to patients with 
epithelial ovarian cancer in Indonesia can affect 
the prognosis and course of epithelial ovarian 
cancer, along with other infl uencing factors such 
as gene expression, chemotherapy response, and 
postoperative factors. Shown that different types 
of therapy given (p = 0.011), together with the 
stage of the disease, were signifi cant prognostic 
factors for patient survival.9 Although the 
difference in therapy is hypothesized to have an 
infl uence on overall survival, there are not many 
other studies that have discussed the difference 
in therapy for survival of patients with epithelial 
ovarian cancer, so further research is still needed.
CONCLUSION
Thrombocytosis was not a prognostic factor 
of epithelial ovarian cancer patients’ survival. 
There were no signifi cant difference of survival 
between epithelial ovarian cancer patients with 
and without thrombocytosis.
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